Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532880 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03532880: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03532880 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03532880, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.
Interventions
- DRUG Olaparib Pill 50 mg
- DRUG Olaparib Pill 100 mg
- DRUG Olaparib Pill 150 mg
- DRUG Olaparib Pill 200 mg
- DRUG Olaparib Pill 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2025-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03532880
The ClinicalTrials.gov registry entry for NCT03532880 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Olaparib Pill 50 mg is the first listed.
NCT03532880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03532880 about?
NCT03532880 is a clinical study titled "A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer". The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.
What is the current status of trial NCT03532880?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-07-12. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT03532880?
The interventions under investigation include: Olaparib Pill 50 mg (DRUG), Olaparib Pill 100 mg (DRUG), Olaparib Pill 150 mg (DRUG), Olaparib Pill 200 mg (DRUG), Olaparib Pill 250 mg (DRUG).
Who is sponsoring clinical trial NCT03532880?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.